Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H41NO6S |
Molecular Weight | 507.683 |
Optical Activity | ( - ) |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C3=CSC(C)=N3
InChI
InChIKey=QXRSDHAAWVKZLJ-PVYNADRNSA-N
InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
Molecular Formula | C27H41NO6S |
Molecular Weight | 507.683 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB03010Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00262990 | https://clinicaltrials.gov/ct2/show/NCT00273312 | https://www.ncbi.nlm.nih.gov/pubmed/27872763 | https://www.ncbi.nlm.nih.gov/pubmed/15860865
Sources: https://www.drugbank.ca/drugs/DB03010
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00262990 | https://clinicaltrials.gov/ct2/show/NCT00273312 | https://www.ncbi.nlm.nih.gov/pubmed/27872763 | https://www.ncbi.nlm.nih.gov/pubmed/15860865
Patupilone is a compound isolated from the myxobacterium Sorangium cellulosum. Similar to paclitaxel, Patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions. In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes. Epothilone B may cause complete cell-cycle arrest. Patupilone failed a phase III trial for ovarian cancer in 2010.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15060743 |
4.7 µM [IC50] | ||
Target ID: CHEMBL1848 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16134928 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
139 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19451434 |
11 mg/m² single, intravenous dose: 11 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PATUPILONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1386 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19451434 |
11 mg/m² single, intravenous dose: 11 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PATUPILONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19451434 |
11 mg/m² single, intravenous dose: 11 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PATUPILONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate [IC50 ~5 uM] | no (co-administration study) Comment: Omeprazole Cmax and AUC(0-12h) were decreased by 21% and 19%. Sources: https://pubmed.ncbi.nlm.nih.gov/21499896/ |
|||
moderate [IC50 ~5 uM] | no (co-administration study) Comment: Midazolam Cmax was reduces by 33% and AUC(0-12h) was increased by 1%. Sources: https://pubmed.ncbi.nlm.nih.gov/21499896/ |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/20966043/ |
no | |||
no | ||||
weak [IC50 25 uM] | no (co-administration study) Comment: S-warfarin Cmax and AUC(0-168h) were increased by 2% and 8%. Sources: https://pubmed.ncbi.nlm.nih.gov/21220503/ |
|||
yes [EC50 12.6 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
no | ||||
yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24937505
Patupilone (Novartis, Basel, Switzerland) was administered
every 3 weeks either as a bolus (20 min), 1-day continuous infusion
(24 h) or 5-day continuous infusion (16-h per day over 5 days) at dose
levels of 6.5, 7.0, 7.5, 8.0, 9.0 and 10.0 mg/m2 until disease progression,
unacceptable toxicity or withdrawal of consent.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27872763
Cortices were dissected from embryonic 15.5mice and incubated in papain (20U/mL, Worthington) containing DNase (10 U/𝜇L, Sigma) for 40min at 37∘C. Enzyme-digested cortices were washed three times with MEM (Cellgro) containing 10% heat inactivated fetal bovine serum (Hyclone) and dissociated in culture medium. Dissociated neurons were then centrifuged to remove the supernatant and counted cells were plated on glass coverslips coated with 100 𝜇g/mL poly-D-lysine (Sigma) and grown in Neurobasal A (Gibco) medium containing Glutamax (1%, Thermo Fisher Scientific) and B27 (2%, Thermo Fisher Scientific) supplements. 5 hr after plating, neurons were treated with epothilone B (from 1 pM to 1 𝜇M and 10pM or 1 nM) for 3 days in low-density cultures (5 x 104 cells in 1.9 cm2) or overnight (17–19hr) in high-density cultures (2 x 105 cells in 1.9 cm2). Neurons were then fixed and analyzed for viability, axon growth, and microtubule structure.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:50:20 GMT 2023
by
admin
on
Fri Dec 15 18:50:20 GMT 2023
|
Record UNII |
UEC0H0URSE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
298809
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
||
|
FDA ORPHAN DRUG |
210205
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
||
|
NCI_THESAURUS |
C1922
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
||
|
NCI_THESAURUS |
C67437
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
||
|
FDA ORPHAN DRUG |
298909
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/09/687
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C093788
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL94657
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
448013
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
C1623
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
8320
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
152044-54-7
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
UEC0H0URSE
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
m4954
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB03010
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
100000126141
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
DTXSID4046862
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
31550
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY | |||
|
SUB33376
Created by
admin on Fri Dec 15 18:50:20 GMT 2023 , Edited by admin on Fri Dec 15 18:50:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
TARGET->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|